Generics BulletinSamsung Bioepis is marking an “important step towards expanding our footprint in Japan,” striking a license, development and commercialization agreement in the country with Osaka-based NIPRO Corporati
Generics BulletinKorean biosimilars player Samsung Bioepis is to be spun out of its parent company Samsung Biologics into a new holding company, tentatively named Samsung Epis Holdings, in an effort to unlock value in
Generics BulletinAmgen and Samsung Bioepis look set to continue marketing their respective biosimilars to Alexion’s Soliris (eculizumab) in the UK, after the UK High Court of Justice’s Patents Court ruled that the fir
Generics BulletinAfter being refused an initial injunction as part of ongoing litigation over a private-label ustekinumab biosimilar being marketed in the US by Sandoz and Samsung Bioepis through a pharmacy benefit ma